UY28700A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- UY28700A1 UY28700A1 UY28700A UY28700A UY28700A1 UY 28700 A1 UY28700 A1 UY 28700A1 UY 28700 A UY28700 A UY 28700A UY 28700 A UY28700 A UY 28700A UY 28700 A1 UY28700 A1 UY 28700A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- relates
- prodrug
- solvate
- medicaments
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0330001A GB0330001D0 (en) | 2003-12-24 | 2003-12-24 | Compounds |
| GB0416850A GB0416850D0 (en) | 2004-07-29 | 2004-07-29 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY28700A1 true UY28700A1 (es) | 2005-07-29 |
Family
ID=34712716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY28700A UY28700A1 (es) | 2003-12-24 | 2004-12-23 | Compuestos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080027076A1 (https=) |
| EP (1) | EP1737462B1 (https=) |
| JP (1) | JP2007517006A (https=) |
| AR (1) | AR046996A1 (https=) |
| AT (1) | ATE402705T1 (https=) |
| DE (1) | DE602004015509D1 (https=) |
| ES (1) | ES2309591T3 (https=) |
| TW (1) | TW200524607A (https=) |
| UY (1) | UY28700A1 (https=) |
| WO (1) | WO2005060969A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410913B (de) * | 2001-08-14 | 2003-08-25 | Schelling Anlagenbau Gmbh | Auflagetisch für eine trennsäge mit einem maschinentisch |
| DE602004018193D1 (de) * | 2003-12-24 | 2009-01-15 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
| US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| EP1863805A1 (en) * | 2005-02-01 | 2007-12-12 | AstraZeneca AB | Pyrimidine compounds having tie2 (tek) inhibitory activity |
| US20080146599A1 (en) * | 2005-02-01 | 2008-06-19 | Astrazeneca Ab | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity |
| GB0502418D0 (en) * | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| JP2008534565A (ja) * | 2005-03-31 | 2008-08-28 | アストラゼネカ アクチボラグ | Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体 |
| AU2013201243A1 (en) * | 2005-12-23 | 2013-03-28 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
| SI1973545T1 (sl) * | 2005-12-23 | 2013-04-30 | Ariad Pharmaceuticals, Inc. | Spojine bicikličnega heteroarila |
| AU2015210454B2 (en) * | 2005-12-23 | 2016-10-27 | Takeda Pharmaceuticals U.S.A., Inc. | Bicyclic heteroaryl compounds |
| EA034598B1 (ru) * | 2005-12-23 | 2020-02-25 | Ариад Фармасьютикалз, Инк. | Применение бициклических гетероарильных соединений для лечения рака |
| US8278307B2 (en) * | 2006-05-08 | 2012-10-02 | Ariad Pharmaceuticals, Inc. | Monocyclic Heteroaryl compounds |
| CN103435595A (zh) | 2006-05-08 | 2013-12-11 | 阿里亚德医药股份有限公司 | 炔类杂芳基化合物 |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| EP2070929A1 (en) * | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| EP2307456B1 (en) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| WO2010012740A1 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| CA2743449C (en) | 2008-11-12 | 2016-10-18 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| CA3022250A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| US10065934B2 (en) | 2014-07-17 | 2018-09-04 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and pharmaceutical uses thereof |
| JP6570776B2 (ja) * | 2016-06-20 | 2019-09-04 | テグ−キョンプク メディカル イノベーション ファウンデーション | 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物 |
| CN109251181B (zh) * | 2017-07-13 | 2021-08-31 | 广东东阳光药业有限公司 | 取代脲衍生物的盐及其在药物中的应用 |
| WO2020013531A1 (ko) * | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| CN110272426B (zh) | 2018-07-17 | 2022-05-31 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物 |
| WO2021172931A1 (ko) * | 2020-02-28 | 2021-09-02 | 재단법인 대구경북첨단의료산업진흥재단 | 3-((8-((1h-피라졸-4-일)아미노)이미다조[1,2-a]피리딘-3-일)에티닐)-n-페닐벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001062233A2 (en) * | 2000-02-25 | 2001-08-30 | F. Hoffmann La Roche Ag | Adenosine receptor modulators |
| JP5154728B2 (ja) * | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ，インコーポレイテッド | 神経栄養活性を有する置換５−アルキニルピリミジン |
| US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| US20030225273A1 (en) * | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
-
2004
- 2004-12-20 AT AT04806134T patent/ATE402705T1/de not_active IP Right Cessation
- 2004-12-20 WO PCT/GB2004/005332 patent/WO2005060969A1/en not_active Ceased
- 2004-12-20 DE DE602004015509T patent/DE602004015509D1/de not_active Expired - Fee Related
- 2004-12-20 US US10/596,740 patent/US20080027076A1/en not_active Abandoned
- 2004-12-20 JP JP2006546305A patent/JP2007517006A/ja active Pending
- 2004-12-20 EP EP04806134A patent/EP1737462B1/en not_active Expired - Lifetime
- 2004-12-20 ES ES04806134T patent/ES2309591T3/es not_active Expired - Lifetime
- 2004-12-23 UY UY28700A patent/UY28700A1/es not_active Application Discontinuation
- 2004-12-24 TW TW093140595A patent/TW200524607A/zh unknown
- 2004-12-27 AR ARP040104907A patent/AR046996A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080027076A1 (en) | 2008-01-31 |
| JP2007517006A (ja) | 2007-06-28 |
| HK1102045A1 (en) | 2007-11-02 |
| EP1737462B1 (en) | 2008-07-30 |
| EP1737462A1 (en) | 2007-01-03 |
| ATE402705T1 (de) | 2008-08-15 |
| TW200524607A (en) | 2005-08-01 |
| WO2005060969A1 (en) | 2005-07-07 |
| AR046996A1 (es) | 2006-01-04 |
| ES2309591T3 (es) | 2008-12-16 |
| DE602004015509D1 (de) | 2008-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY28700A1 (es) | Compuestos | |
| UY28701A1 (es) | Compuestos | |
| UY30310A1 (es) | Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| UY31524A1 (es) | Nuevos compuestos 010 | |
| CY1113573T1 (el) | Selurampanel | |
| AR053412A1 (es) | Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos | |
| SE0302811D0 (sv) | Novel compounds | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| ECSP10010013A (es) | Nuevos fungicidas | |
| ATE522249T1 (de) | Organische verbindungen | |
| MA28550B1 (fr) | Composes et procedes permettant de traiter la dyslipidemie | |
| GEP20115174B (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| CY1116885T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου | |
| BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
| PA8785401A1 (es) | Derivados de bencimidazol | |
| TW200732335A (en) | Organic compounds | |
| ECSP056134A (es) | Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3 | |
| ECSP088677A (es) | Piperazinas y piperidinas como potenciadores 157 del mglur5 | |
| BRPI0413151A (pt) | derivados de amino propanol | |
| PA8573501A1 (es) | Derivados de benzoxazina y su empleo | |
| CY1113733T1 (el) | Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων | |
| BRPI0519292A2 (pt) | compostos orgÂnicos | |
| BRPI0511610A (pt) | derivados de amino-propanol | |
| UY27980A1 (es) | Indoles 2,7-sustituidos | |
| TW200732337A (en) | Organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20150529 |